Introduction {#s1}
============

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that affects approximately 1% of the population worldwide [@pone.0089442-Harris1]. OLE_LINK10Although the introduction of anti-TNFα agents has dramatically improved the outcome of RA, there unfortunately remains a proportion of RA patients who do not exhibit an adequate response to this treatment. Considering the high cost and potential side effects of anti-TNFα treatment, it is important to identify those RA patients who will be more likely to respond to these agents. Indeed, numerous studies have been conducted to investigate potential predictors for patient response to anti-TNFα therapy [@pone.0089442-Radovits1]--[@pone.0089442-Gibbons1].

Both rheumatoid factor (RF) and antibodies against cyclic citrullinated peptide (anti-CCP) are regarded as serological markers of RA [@pone.0089442-Pruijn1], [@pone.0089442-Avouac1]. Some studies have suggested that the status of RF or anti-CCP antibody in RA patients is associated with a clinical response to anti-TNFα treatment [@pone.0089442-Vasilopoulos1]--[@pone.0089442-BraunMoscovici1], whereas such a correlation was not found in other studies [@pone.0089442-Soto1]--[@pone.0089442-Alexandra1]. Thus, no definite conclusion has been reached to date.

We performed a meta-analysis to investigate whether RF and anti-CCP have predictive value for a clinical response to anti-TNFα treatment. Suitable studies investigating an association of the status of RF or anti-CCP and response to anti-TNFα treatment were searched and included. We also performed subgroup analyses on different variables to explore potential sources of independent predictive factors for an effect of anti-TNFα treatment.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

A literature search was performed for all studies evaluating an association between the status of RF or anti-CCP antibody and a response to anti-TNFα therapy in RA patients using the Medline, Cochrane Library, SCOPUS (including EMbase), ISI Web of Knowledge, and Clinical Trials Register (clinical trials.gov) databases. The following keywords were searched: rheumatoid arthritis, anti-TNFα, rheumatoid factor, anti-cyclic citrullinated peptide antibody, clinical trials, and systematic review. Synonyms and spelling variations were taken into account (Search strategy for Scopus was listed in [Table S1 in File S1](#pone.0089442.s001){ref-type="supplementary-material"}). There was a limitation with regard to language, i.e., we only considered English publications, but not the year of publication. We also contacted authors to request a full-text review or specific data from studies when there was no electronic version of the full text or sufficient data for the meta-analysis. Citations were reviewed to search relevant original studies, and an electronic search alert was set to cover recent studies.

Study selection {#s2b}
---------------

There were 1649 references identified by the literature search. Three individual investigators (QL, YY, & XL) evaluated the references, and the decision of inclusion was made by consensus. A study was included based on the following criteria: 1) the patients were older than 16 years old, diagnosed with RA using ACR criteria, and treated with at least one anti-TNFα agent (adalimumab, infliximab, etanercept, certolizumab, or golimumab); 2) efficacy was measured using EULAR or ACR or DAS28 criteria after a minimum duration of 12 weeks; and 3) the status of RF or anti-CCP antibody at baseline and sufficient data to calculate the risk ratio (RR) were reported in the study. The following information was extracted from each study: the study design, patients\' characteristics, baseline status of RF or anti-CCP antibody, interventions, outcomes, and study duration.

Study assessment {#s2c}
----------------

All of the studies included were evaluated for potential bias using Hayden\'s criteria of the quality assessment of prognostic studies [@pone.0089442-Hayden1] (The details of the modified criteria were provided in [Table S2 in File S2](#pone.0089442.s002){ref-type="supplementary-material"}). Six domains were considered in the bias assessment method: "study participation", "study attrition", "prognostic factor measurement", "outcome measurement", "confounding measurement and account", and "analysis". Scores of "0", "1", or "2" represented "high bias", "partial bias", and "low bias", respectively. If the available information was insufficient to obtain a decision after contacting the authors, "unsure" was used, and no score was calculated. The total scores were calculated to show the level of study quality; studies with a score of "11--12" were rated as having relatively high quality, with "9--10" as moderate, and "less than 8" as low quality. The evaluation was performed independently by three investigators (QL, YY, & XL) to improve the validity of the results.

Statistical analysis {#s2d}
--------------------

We estimated the risk ratio of the RF or anti-CCP antibody status for a response to anti-TNFα treatment. The point estimate of the risk ratio (RR) and 95% confidence intervals (CI) were calculated for each study, and a Mantel Haenszel analysis was used to calculate the pooled RR and 95% CI. The heterogeneity of the effects across studies was assessed using the Chi square test and qualified by I^2^ values, which represent the proportion of between-study variability that is attributable to heterogeneity rather than to chance; I^2^ values of 25%, 50%, and 75% are referred to as low, moderate, and high heterogeneity effects, respectively. A fixed-effects model was used when there was no significant heterogeneity, whereas a random-effects model was used in other cases. Subgroup analyses were performed to investigate potential sources of heterogeneity by stratifying the different anti-TNFα agents, response criteria, duration of follow-up, and ethnic group. In addition, a sensitivity analysis was performed by the sequential omission of individual studies. Publication bias was estimated by funnel plots and an Egger\'s test, with p\<0.05 considered as representing significant bias. All of the statistical analyses were performed using Review Manager 5.0 software, and the results of the publication bias were estimated using STATA 12.0 software.

Results {#s3}
=======

Characteristics of the included studies {#s3a}
---------------------------------------

[Figure 1](#pone-0089442-g001){ref-type="fig"} describes the flowchart of our literature search. According to pre-determined criteria, fifteen articles, published between 2006 and 2012, were included [@pone.0089442-Vasilopoulos1], [@pone.0089442-Potter1]--[@pone.0089442-Alexandra1], [@pone.0089442-Wijbrandts1]--[@pone.0089442-Keystone1] (A list of articles excluded and the reasons for exclusion were presented in [Table S3 in File S1](#pone.0089442.s001){ref-type="supplementary-material"}). As two described the same cohort [@pone.0089442-Klaasen1], [@pone.0089442-Wijbrandts1], fourteen studies were ultimately included in this meta-analysis [@pone.0089442-Vasilopoulos1], [@pone.0089442-Potter1], [@pone.0089442-Mancarella1], [@pone.0089442-Cuchacovich1]--[@pone.0089442-Alexandra1], [@pone.0089442-Wijbrandts1]--[@pone.0089442-Keystone1]. These studies comprised a total of 5561 RA patients: 5374 patients had their status of RF detected, and 1283 patients had their status of anti-CCP antibody detected. All but one were prospective cohort studies. All of the participants in the 14 studies had active RA, as evaluated by the number of swollen and tender joints, or DAS28 value, and the patients in all but one_ENREF_7 study had exhibited failure for at least one type of Disease-modifying Anti-Rheumatic Drug (DMARD) treatment [@pone.0089442-Canhao1]. Almost all of the patients had established RA, with a mean disease duration from 5 to 14 years. The data extracted from the 14 studies are summarized in [Table 1](#pone-0089442-t001){ref-type="table"}. With regard to the anti-TNFα agents utilized, 10 studies involved infliximab, 8 involved adalimumab, 6 involved etanercept, and 1 involved golimumab.

![Flowchart of the study selection.](pone.0089442.g001){#pone-0089442-g001}
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###### Data extracted from the included studies.

![](pone.0089442.t001){#pone-0089442-t001-1}

  Study                           Study design               No. of patients   Disease duration (yrs)    Age (yrs)    Gender (female%)   No. of swollen joints   No of tender joints      DAS28      Prior biologic used[\#](#nt102){ref-type="table-fn"}                       Intervention                            Country        Primary clinical outcome (response criteria)   Study duration                   Antibody measurement                   Cut-off value of antibody
  ------------------ -------------------------------------- ----------------- ------------------------ ------------- ------------------ ----------------------- --------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ------------------- ---------------------------------------------- ---------------- ------------------------------------------------------ ---------------------------
  Braun2006           Pro[\*](#nt101){ref-type="table-fn"}         30                 12 (8.9)          50.6 (13.9)         73%                   N/A                    N/A           7.4 (0.95)                            N/A                                                INF+86.7%MTX                            Israel                            EULAR                           3.5 m                          Anti-CCP: ELISA                               5 IU/ml
  Hyrich2006                          Pro                         2879                 14 (9)             55 (12)           78%                 12 (6)                 16 (7)           6.7 (1.0)                            N/A                                 ETA+28%MTX: 1267 pts; INF+86%MTX: 1612 pts             Britain                           EULAR                            6 m                                 N/A                                       N/A
  Bobbio2007                          Pro                          126               8.3 (6.9)          57.3 (12.5)        76.5%               9.6 (5.7)             16.0 (9.9)        5.87 (0.99)                           N/A                                       INF/ADA/ETA+CSs/NSAIDs allowed                    Italy                            EULAR                            12 m              RF: immunonephelometry; Anti-CCP: ELISA              15 IU/ml; 5 IU/ml
  Lequerre2007                        Pro                          76                10.5(8.6)          53.8(12.4)         81.6%                13.8(6)               10.7(7.3)          5.8(1)                              N/A                                                INF+MTX/LEF                             France                            EULAR                           3.5 m           RF: latex agglutination test;; Anti-CCP: ELISA                 N/A
  Mancarella2007                     Retro                         591               11.6 (7.6)         53.3 (12.7)         67%               10.4 (7.1)             17.1 (9.4)         5.9 (1.2)                            N/A                                                INF/ETA/ADA                              Italy                            EULAR                            6 m                                 N/A                                    20 IU/ml
  Wijbrandts2007                      Pro                          103               10.4 (9.2)           55 (13)           69%                   N/A                    N/A            5.9 (1.1)                            None                                          INF+CSs/NSAIDs allowed                   The Netherlands                       DAS28                            4 m                                 N/A                                       N/A
  Cuchacovich2008                     Pro                          59                   11.7               48.9             87%                  16.2                    20                N/A                               N/A                                         ADA+DMARDs/NSAIDs allowed                       Chile                            ACR20                            6 m                           Anti-CCP: ELISA                              25 IU/ml
  Wouter2008                          Pro                          172                  8.5                53.7            79.3%                  N/A                    N/A               5.1                               N/A                                             ADA+74%MTX+34%CSs                      The Netherlands                       EULAR                            7 m                      RF: ELISA; Anti-CCP: ELISA                    30 IU/ml; 5 AU/ml
  Alexandra2009                       Pro                          36                10.2 (5.8)         50.5 (10.2)         75%                7.4 (5.3)               9.5 (5)          5.2 (0.9)                            None                                               INF+91.6%MTX                            France                            EULAR                            12 m        RF: quantitative nephelometric test; Anti-CCP: ELISA     1000 IU/ml; 200 IU/ml
  Keystone2009                        Pro                          179                  5.3                 52             80.9%                 12.5                   24.5              6.008                              N/A                                                  GOL+MTX                          From 12 countries                      ACR20                           3.5 m                                N/A                                       N/A
  Potter2009                          Pro                          642                14 (10)             57 (11)           78%                   N/A                    N/A             6.7 (1)                             N/A                                  ADA: 62 pts; ETA: 241 pts; INF: 218 pts               Britain                           EULAR                            6 m               RF; immunoturbidimetry; Anti-CCP: ELISA               40 U/ml; 5 U/ml
  Soto2010                            Pro                          52                   11.9                50             88.5%                 16.9                   21.4               5.8                               N/A                                    ADA+stable DMARDs/NSAIDs/CSs allowed                 Chile                      DAS28; ACR20/50/70                     6 m                      RF: ELISA; Anti-CCP: ELISA                      N/A; 25 IU/ml
  Vasilopoulos2011                    Pro                          100               13.6 (6.5)         57.4 (10.8)         92%                   N/A                    N/A            5.6 (0.2)                            N/A                            INF+MTX: 24 pts; ETA±MTX: 26 pts; ADA±MTX/LEF:50 pts        Greece                            DAS28                            6 m               RF: immunonephelometry; Anti-CCP: ELISA              15 IU/ml; 5 U/ml
  Canhao2012                          Pro                          516               10.4 (8.6)         50.9--54.1          88%                 8 (5.4)              11.5 (7.3)         5.8 (1.2)                            None                                          INF/ADA/ETA±DMARDs/CSs                      Portugal                           EULAR                            6 m                              RF: ELISA                         IgM:5 IU/ml; IgA:20 IU/ml

\*Pro, prospective clinical trial; Retro, retrospective study; N/A, not available; INF, infliximab; ADA, adalimumab; ETA, etanercept; MTX, methotrexate; LEF, leflunomide; NSAIDs, non-steroidal anti-inflammatory drugs; DMARDs, disease-modifying anti-rheumatic drugs; CSs, corticosteroids.

Different prior biologic agents used may introduce potential heterogeneity, though the available data were insufficient for a sub-analysis.

Disease of duration, age, No. of swollen joints, No. of tender joints, DAS28 are presented as the mean (SD).

There was no study that involved patients receiving certolizumab. Only four studies investigated the status of RF, with only two investigating anti-CCP; the other eight studies measured both RF and anti-CCP. The follow-up duration of these 14 studies ranged from 14 weeks to 48 weeks.

Study quality {#s3b}
-------------

Our assessment was performed on the basis of Hayden\'s criteria for prognostic studies [@pone.0089442-Hayden1]. The results revealed that only one of the included studies was considered to be of low quality, with a score of 7; the other thirteen studies were considered as having moderate or high quality (11 moderate and 2 high) ([Table 2](#pone-0089442-t002){ref-type="table"}).

10.1371/journal.pone.0089442.t002

###### The results of an assessment for bias in accordance with Hayden\'s criteria.

![](pone.0089442.t002){#pone-0089442-t002-2}

                        Assessment domain                                               
  -------------------- ------------------- ---------- ---------- ----- ---------- ----- ------------------------------------
  Braun, 2006               moderate          low      moderate   low     low      low                   10
  Hyrich, 2006                 low            low       unsure    low   moderate   low   9[\*](#nt106){ref-type="table-fn"}
  Bobbio, 2007                 low            low        low      low     high     low                   10
  Lequerre, 2007               low            low      moderate   low   moderate   low                   10
  Mancarella, 2007             low            high     moderate   low     high     low                   7
  Wijbrandts, 2007             low          moderate     low      low   moderate   low                   10
  Cuchacovich, 2008         moderate        moderate     low      low   moderate   low                   10
  Wouter, 2008                 low            low        low      low   moderate   low                   11
  Alexandra, 2009           moderate          low      moderate   low   moderate   low                   9
  Keystone, 2009              high            low      moderate   low     low      low                   9
  Potter, 2009                 low          moderate     low      low   moderate   low                   10
  Soto, 2010                moderate          low      moderate   low   moderate   low                   9
  Vasilopoulos, 2011           low            low        low      low   moderate   low                   11
  Canhao, 2012                 low          moderate   moderate   low   moderate   low                   9

Unsure: not enough information to evaluate.

Low, low risk of bias; moderate, moderate risk of bias; high, high risk of bias.

\*One of the domains was assessed as "unsure" due to unavailable information even after the authors were contacted.

Association evaluation of RF/anti-CCP antibody status and patient response to anti-TNFα agents {#s3c}
----------------------------------------------------------------------------------------------

Twelve of the included studies, with a total of 5374 patients, examined the predictive effect of the RF status for patient response to anti-TNFα agents. The overall analysis revealed that the pooled RR was 0.98 (95% CI: 0.91--1.05, p = 0.54) and that I^2^ was 43% ([Figure 2a](#pone-0089442-g002){ref-type="fig"}), suggesting that the RF status was not associated with a patient\'s response to anti-TNFα treatment, with a moderate heterogeneity observed. Subgroup analyses on the different anti-TNFα agents, follow-up periods, response criteria, and ethnic groups were performed to investigate sources of this heterogeneity, though the results revealed no significant differences ([Figure 2b](#pone-0089442-g002){ref-type="fig"}, [Table 3](#pone-0089442-t003){ref-type="table"}).

![Forest graphs of the meta-analysis of RF status and response to anti-TNFα agents.\
The overall analysis of RF status showed a pooled RR of 0.98 (95% CI: 0.91--1.05, p = 0.54) and an I^2^ of 43%. Subgroup analyses on different response criteria revealed no significant differences.](pone.0089442.g002){#pone-0089442-g002}

10.1371/journal.pone.0089442.t003

###### Subgroup meta-analysis of RF and RA patient response according to different anti-TNFα agents, follow-up periods, response criteria, and ethnic groups.

![](pone.0089442.t003){#pone-0089442-t003-3}

                                                                                   Test of association   Test of heterogeneity                     
  -------------------------------------------------- ---------------- ---- ------ --------------------- ----------------------- ------ ---- ------ -----
                                                         overall       12   5374          0.98                0.91--1.05         0.54   R    0.05   43%
  Anti-TNFα agent[\*](#nt108){ref-type="table-fn"}      infliximab     4    1827          1.03                0.89--1.19         0.71   R    0.28   23%
                                                        adalimumab     2    248           0.98                0.81--1.18         0.8    R    0.09   65%
                                                        etanercept     1    1267          1.05                0.97--1.12         0.21   NA    NA    NA
                                                        golimumab      1    178           1.54                0.93--2.55         0.09   NA    NA    NA
  Follow up period                                      ≥6 months      9    5017          0.96                0.90--1.03         0.27   R    0.13   37%
                                                        \<6 months     3    357           1.25                0.87--1.78         0.22   R    0.11   54%
  Ethnic group                                           European      10   5146          0.98                0.91--1.06         0.59   R    0.10   39%
                                                      South American   1     50           0.89                0.76--1.06         0.19   NA    NA    NA

R, random-effects model; NA, not applicable.

\*The number of studies and number of patients receiving individual anti-TNFα agent in this table are those that we could identified after literature review and contacting the authors.

Ten studies, with a total of 1283 RA patients, were analyzed for an association of anti-CCP antibody status and patient response to anti-TNFα treatment. The overall meta-analysis showed no association between the status of anti-CCP antibody and a patient\'s response to anti-TNFα treatment, with a pooled RR of 0.88 (95% CI: 0.76--1.03, p = 0.11) and an I^2^ of 67% ([Figure 3a](#pone-0089442-g003){ref-type="fig"}). When we performed a subgroup analysis to explore potential heterogeneity, we did not identify any association by stratifying the studies using either different anti-TNFα agents, follow-up periods, response criteria, or ethnic groups ([Figure 3b](#pone-0089442-g003){ref-type="fig"}, [Table 4](#pone-0089442-t004){ref-type="table"}).

![Forest graphs of the meta-analysis of anti-CCP antibody status and response to anti-TNFα agents.\
The overall analysis of anti-CCP antibody status showed a pooled RR of 0.88 (95% CI: 0.76--1.03, p = 0.11) and an I^2^ of 67%. Subgroup analyses on different response criteria revealed no significant differences.](pone.0089442.g003){#pone-0089442-g003}

10.1371/journal.pone.0089442.t004

###### Subgroup meta-analysis of anti-CCP and RA patient response according to different anti-TNFα agents, follow-up periods, response criteria, and ethnic groups.

![](pone.0089442.t004){#pone-0089442-t004-4}

                                                                                   Test of association   Test of heterogeneity                         
  -------------------------------------------------- ---------------- ---- ------ --------------------- ----------------------- -------- ---- -------- -----
                                                         overall       10   1283          0.88                0.76--1.03          0.11    R    \<0.01   67%
  Anti-TNFα agent[\*](#nt110){ref-type="table-fn"}      infliximab     5    345           0.79                0.55--1.13          0.19    R    \<0.01   78%
                                                        adalimumab     3    297           1.01                0.88--1.17          0.86    F     0.69    0%
  Follow up period                                      ≥6 months      7    1074          0.90                0.80--1.01          0.06    R     0.09    46%
                                                        \<6 months     3    209           0.78                0.40--1.53          0.47    R    \<0.01   86%
  Ethnic group                                           European      7    1144          0.90                0.79--1.04          0.17    R     0.02    60%
                                                      South American   2    109           1.01                0.79--1.30          0.91    F     0.38     0
                                                          Asian        1     30           0.37                0.20--0.66         \<0.05   NA     NA     NA

F, fixed-effects model; R, random-effects model; NA, not applicable.

\*The number of studies and number of patients receiving individual anti-TNFα agent in this table are those that we could identified after literature review and contacting the authors.

Sensitivity and publication bias {#s3d}
--------------------------------

Sensitivity analyses were performed based on the results of the bias assessments, Hayden\'s criteria of quality assessment for prognostic studies, by the sequential omission of individual studies, and the result revealed that the significance estimate of the overall pooled RR was not influenced by omitting any single study. The publication bias was evaluated by a funnel plot, which showed no significant evidence of asymmetry ([Figures 4](#pone-0089442-g004){ref-type="fig"}--[5](#pone-0089442-g005){ref-type="fig"}). We also performed an Egger\'s linear regression test to quantify the publication bias. The p values of the RF and anti-CCP antibody status analyses were 0.777 and 0.422 ([Figures 4](#pone-0089442-g004){ref-type="fig"}--[5](#pone-0089442-g005){ref-type="fig"}), and all other Egger\'s test p values in this meta-analysis were \>0.05, suggesting no significant bias in the analysis.

![Overall analysis of publication bias on the effect of RF status on the response to anti-TNFα treatment.\
Egger\'s linear regression test was performed to quantify publication bias. The p values of the RF status analysis were 0.777. The funnel plot showed no significant evidence of asymmetry.](pone.0089442.g004){#pone-0089442-g004}

![Overall analysis of publication bias on the effect of anti-CCP antibody status on the response to anti-TNFα treatment.\
Egger\'s linear regression test was performed to quantify publication bias. The p values of the anti-CCP antibody status analysis were 0.422. The funnel plot showed no significant evidence of asymmetry.](pone.0089442.g005){#pone-0089442-g005}

Discussion {#s4}
==========

Previous single studies have suggested that the presence of RF and anti-CCP antibody is associated with a reduced response to anti-TNFα treatment [@pone.0089442-Vasilopoulos1]--[@pone.0089442-BraunMoscovici1];\_ENREF_9 however, a number of studies have reported a contrasting conclusion [@pone.0089442-Soto1]--[@pone.0089442-Alexandra1]. Thus, to investigate whether the status of RF or anti-CCP antibody in RA patients has predictive value for a clinical response to anti-TNFα treatment, we performed a meta-analysis by a comprehensive literature search and inclusion of all of the available qualifying studies. The results of our meta-analysis demonstrated that there was no association between the status of RF and patient response to anti-TNFα treatment. Furthermore, the status of anti-CCP antibody was also not associated with patient response, with a pooled RR of 0.88 and 95% CI of 0.76--1.03 (p = 0.11), indicating a tendency of association between the absence of anti-CCP antibodies and a patient\'s response to anti-TNFα therapy. Therefore the cumulative results did not support or completely reject the association between the presence of RF and/or anti-CCP and the effect of treatment with TNFα inhibitors. Anti-CCP is an independent predictor of radiological damage and progression in RA patients [@pone.0089442-Forslind1], [@pone.0089442-Bongi1], and anti-CCP-positive patients have a relatively worse prognosis. As a result, patients with a different anti-CCP antibody status may have a different baseline of the disease, which could influence their response to anti-TNFα agents. To explore this influence, analyses should be performed to investigate potential differences in the baseline characteristics between groups stratified by the status of anti-CCP antibody. Alternatively, only analyses based on studies with placebo groups are powered to definitively identify such an association. Unfortunately, such information was not available for the included studies.

This meta-analysis does have some limitations. First, only 14 studies were included in this meta-analysis, with 12 studies reporting the status of RF and 10 studies reporting the status of anti-CCP antibody. Nonetheless, after a comprehensive literature search covering five databases and the selection of eligible studies by three different investigator strictly according to the inclusion criteria, most of the included studies were assessed with moderate-to-high quality. Therefore, it is reasonable to obtain a conclusion based on the studies included in this meta-analysis. However, as potential heterogeneity exists between studies after subgroup analyses were performed, the result of our analyses should be interpreted with caution, and our conclusions should be updated using new, larger studies in the future. Secondly, all of the patients in the studies included in our meta-analysis had long-standing disease, with a mean value of disease duration ranging from 5 to 14 years, and had previously shown failure with at least one type of DMARD. Indeed, patients with more severe chronic disease as a result of irreversible joint damage may be less likely to respond to anti-TNFα treatment [@pone.0089442-Hyrich1]. Thirdly, most of the included studies reported a combined treatment of DMARDs in a proportion of the patients enrolled. Because studies have demonstrated improved outcomes among patients receiving combination therapy with MTX plus anti-TNFα [@pone.0089442-Hyrich1], the heterogeneity of combined therapy among the studies may have introduced potential bias.

In summary, our meta-analysis indicated that the status of RF and anti-CCP are not associated with the clinical response to anti-TNFα treatment in RA patients.
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